Tech Company Inital Public Offerings

Deciphera Pharmaceuticals IPO

Deciphera Pharmaceuticals, based in Waltham, debuted as a public company on 9/27/2017.

Transaction Overview

Announced On
9/27/2017
Transaction Type
IPO
Amount
$127,500,000
Proceeds Purpose
We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: approximately $60 million to fund clinical trials for DCC-2618, including the dose escalation and expansion stages of our current Phase 1 clinical trial and additional clinical trials, including a pivotal clinical trial in fourth-line GIST, as well as clinical research outsourcing and manufacturing of clinical trial material; approximately $6 million to fund clinical trials for DCC-3014, including the dose escalation stage of our Phase 1 clinical trial, as well as clinical research outsourcing and manufacturing of clinical trial material; approximately $6 million to fund clinical trials for rebastinib, as well as clinical research outsourcing and manufacturing of clinical trial material; approximately $10 million to fund the new and ongoing research activities for future drug candidates using our proprietary kinase switch control inhibitor platform; and the remainder

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
200 Smith St.
Waltham, MA 02451
USA
Email Address
Overview
Deciphera Pharmaceuticals (NASDAQ: DCPH) was established in 2003 as a drug discovery and development company with the mission to design, optimize and introduce best-in-class small molecule switch inhibitors of protein kinases for human clinical trials and the global pharmaceutical marketplace through the use of its proprietary drug discovery technology platform.
Profile
Deciphera Pharmaceuticals LinkedIn Company Profile
Social Media
Deciphera Pharmaceuticals Company Twitter Account
Company News
Deciphera Pharmaceuticals News
Facebook
Deciphera Pharmaceuticals on Facebook
YouTube
Deciphera Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Steven Hoerter
  Steven Hoerter LinkedIn Profile  Steven Hoerter Twitter Account  Steven Hoerter News  Steven Hoerter on Facebook
Chief Financial Officer
Tucker Kelly
  Tucker Kelly LinkedIn Profile  Tucker Kelly Twitter Account  Tucker Kelly News  Tucker Kelly on Facebook
Chief Scientific Officer
Daniel Flynn
  Daniel Flynn LinkedIn Profile  Daniel Flynn Twitter Account  Daniel Flynn News  Daniel Flynn on Facebook
VP - General Counsel
Jeffrey Held
  Jeffrey Held LinkedIn Profile  Jeffrey Held Twitter Account  Jeffrey Held News  Jeffrey Held on Facebook
VP - Human Resources
Peter Lasky
  Peter Lasky LinkedIn Profile  Peter Lasky Twitter Account  Peter Lasky News  Peter Lasky on Facebook


 

 

Browse more venture capital transactions:

Prev: 9/27/2017: Deep Genomics venture capital transaction
Next: 9/27/2017: Transit venture capital transaction

 

Share this article

 


About Our VC Transactions Data

Our team works diligently to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary